Optum Rx®

Drug Pipeline Insights Report

September 2024 Summary

Dupixent® (dupilumab)
Expected FDA decision: Sept. 27, 2024

Dupixent is seeking a new indication to treat moderate-to-severe chronic obstructive pulmonary disease (COPD) with type 2 inflammation. COPD can lead to chronic breathing problems and is the sixth leading cause of death in the U.S.

Dupixent blocks the signaling proteins that help activate the body's immune and inflammation responses. Blocking these signals helps reduce inflammation caused by COPD.

Dupixent would be the first biologic approved for COPD. In trials, Dupixent demonstrated significant improvement in reducing COPD flare-ups and was generally well tolerated.

The Wholesale Acquisition Cost (WAC) for Dupixent is approximately $49,000 per year.

Xanomeline/trospium: Brand name TBD
Expected FDA decision: Sept. 26, 2024

Xanomeline/trospium is a new treatment for schizophrenia.

Xanomeline/trospium could provide an alternative or an addition to existing front-line antipsychotic therapies. It also shows potential to treat psychosis in patients with Alzheimer's disease, which would widen its market.

In trials, xanomeline/trospium appears to be as effective as current treatment options, but produces less weight gain, involuntary movements, tremors, and muscle contractions.

Prices are not available, but Caplyta® (lumateperone) – a common antipsychotic – has a wholesale acquisition price of approximately $20,000 per year.